According to recent research studies, patients hospitalized with COVID-19 are at high risk of developing venous thromboembolism (VTE), a potentially deadly condition in which a blood clot forms in the deep veins of the leg, groin or arm (known as a deep vein thrombosis, or DVT) and may dislodge. If that happens, the clot can travel via the bloodstream to lodge in the lungs and cause tissue damage or death from reduced oxygen (known as a pulmonary embolism, or PE). It has recently been thought that missed doses of anti-clotting drugs in patients with COVID-19 in hospital settings might contribute to increased rates of hospital-associated VTEs.